Answers are grounded in this paper and cite their sources.
Sickle cell disease (SCD) is a group of genetic disorders characterized by the presence of an aberrant hemoglobin molecule, hemoglobin S. This leads to characteristic sickling of erythrocytes. In SCD, the sickled RBC clump together, causing vascular crisis, which is the most significant contributor to morbidity and mortality. This vascular complication causes a variety of manifestations such as vaso-occlusive crises, acute chest syndrome, stroke, and chronic organ damage. Early identification of SCD patients who are at risk for developing vascular complications is the most important preventive measure and management strategy for SCD. CD34 is a cell surface marker expressed on hematopoietic stem cells (HSC). CD34 is generally reported to decrease in vascular complication which caused complications. Thus, CD34 has emerged as a potential prognostic marker for vascular complications in SCD. This review aims to establish a link between progressive vascular complications in SCD and HSC.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: